Drug Profile
ARRY 300
Alternative Names: ARRY-300Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)